<DOC>
	<DOCNO>NCT01617200</DOCNO>
	<brief_summary>Participants complete 6-week trial P05688 screen eligibility 26-week extension study continue treatment . The purpose trial evaluate long-term safety 2.5 5 mg asenapine administer sublingually twice daily ( BID ) schizophrenia participant . Olanzapine administer 15 mg orally daily ( QD ) use active control .</brief_summary>
	<brief_title>Long-Term Safety Extension Trial Asenapine Schizophrenia Participants Who Completed Protocol P05688 ( P05689 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Completed shortterm trial P05688 , judge investigator likely benefit continue treatment Occurrence ( ) adverse event clinically significant finding ( ) shortterm trial P05688 would prohibit participant 's continuation longterm extension Clinical Global ImpressionSeverity Illness ( CGIS ) score â‰¥6 ( severely psychotic ) Baseline Newly diagnose discover psychiatric condition would exclude participant participation shortterm trial P05688</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>